- Management Team Leadership is responsible for the design and development of business and investment strategies and, upon Board approval, the execution of strategies, administrative operations, and organizational growth of GHIT.
Dr. Slingsby is CEO & Executive Director of the GHIT Fund — the World's first public-private fund focused on the development of new medicines for low- and middle-income countries. Previously, he was the global head for access strategies at Eisai Co., Ltd. where he developed new business models for R&D and overlooked market access in the developing world. Dr. Slingsby has helped launch numerous start-ups in Japan and the U.S., and currently advises at the Graduate School of Medicine at the University of Tokyo and Kyoto University. He is a member of the Public-Private Partnership Forum at the National Academy of Medicine in the U.S. and the Global Health and Human Security Program, and has published over 50 peer-reviewed articles on medicine and public health in both Japanese and, American literature. Dr. Slingsby graduated from Brown University, earned his Masters and Doctorate from Kyoto University, and the University of Tokyo, and received his Medical Doctorate from the George Washington University.
Kio Yamabe is Chief Operating Officer at the GHIT Fund, where he leads operations, human resources, legal and compliance, and also oversees finance and investment. Mr. Yamabe has more than 25 years of management experience in the pharmaceutical and healthcare industry, including as President and Country Manager of Carestream Health and CSL Behring. He has lived and worked in Australia, Switzerland, the United Kingdom, and the United States, including as Head of International Business at First Retailing Co., Ltd., where he led the launch of UNIQLO stores in London. He received his MBA from IMD in Switzerland and a BS from Seinan Gakuin University in Japan.
Masayuki Sato currently serves as Vice President of External Engagement, bringing a wealth of experience from the pharmaceutical sector where he worked previously, including for such companies as Toray, Otsuka, and GlaxoSmithKline (GSK) in areas of corporate strategy and planning, sales strategy, business development and external relations. Previously, Mr. Sato was a founding member of two start-up joint ventures for GSK: ViiV Healthcare with Pfizer/Shionogi, and Japan Vaccine with Daiichi-Sankyo. He holds an MBA from Keio University, and a Bachelor of Economics from Hokkaido University in Japan. He is a Chartered Member of the Security Analysts Association of Japan (CMA).
Kei Katsuno is Senior Director of Investment Strategy & Government Relations at the GHIT Fund. Previously, he worked as a Health Specialist at the World Bank, following his completion of a fellowship at the Asia Pacific Leadership Program at the East West Center. Dr. Katsuno graduated from the University of Tokyo with a medical degree and worked as a medical doctor in the Emergency Medicine Department of the National Center for Global Health and Medicine (formerly International Medical Center of Japan). He possesses both Japanese and U.S. medical licenses (ECFMG) and completed the MPH program at the Johns Hopkins University as a Fulbright Scholar. He is a lecturer at the Department of Biomedical Chemistry, Graduate School of Medicine at the University of Tokyo, and a fellow of the U.S.-Japan Leadership Program.
Bumpei Tamamura is Senior Director of Brand Communications. Previously, he worked as a strategic planner at a communication agency and social marketing venture. He supported a wide range of clients from international organizations, government ministries, universities, research institutions, and pharmaceutical companies. Mr. Tamamura graduated from the Tokyo University of Pharmacy and Life Sciences, and received his MPH from Boston University School of Public Health.
Miho Takazawa is Director of Finance at the GHIT Fund. Previously, she was Finance Manager in charge of Corporate/Special Purpose Company (SPC) Accounting and Treasury at Mapletree Investments Japan K.K., a Singaporean Real Estate Investment/Asset Management Company based in Japan. Prior to that she served in the Accounting Department at Fuji Bank/Mizuho Corporate Bank (now Mizuho Bank) in New York City. She holds an MBA and a BS in International Business from Southern New Hampshire University in the United States and a BA in the History of Chinese Thought from Atomi University in Japan.
Hayato Urabe is Director of Investment Strategy and Management at the GHIT Fund, where he oversees all portfolio management activities. Previously, Dr. Urabe held several positions across the energy, life sciences, and water treatment sectors, focusing on strategy planning, start-up due diligence, and project management in Silicon Valley. He was also a consultant at Synthetic Genomics for technologies ranging from nutrigenomics to biofuels.
Dr. Urabe completed his Bachelor of Science in Molecular Biology, Master of Science in Innovation Management and Entrepreneurship Engineering, and Doctor of Philosophy in Biomedical Engineering from Brown University. In addition, Dr. Urabe earned as Master’s degree from the School of Global Policy and Strategy at University of California, San Diego.